Sky Labs, a South Korea-based medical technology company, announced on Monday that it has shared clinical research outcomes of its ring-type blood pressure monitor, CART, at ESC Congress 2026 in Munich, Germany.
Sky Labs hosted five dedicated sessions presenting new clinical data on atrial fibrillation (AF) and heart failure (HF) patients for the first time.
Professor Ki-Hong Lee (Chonnam National University Hospital) presented a 24-hour BP monitoring study on AF patients, stating: "Using the CART blood pressure monitor, we achieved an analysable data rate of approximately 80%, demonstrating the utility of ring-type 24-hour BP testing and enabling continuous observation of nocturnal dipping patterns."
Professor In-Cheol Kim (Keimyung University Dongsan Hospital) shared research on severe HF patients (mean EF 29%), noting: "A simultaneous comparison between the CART blood pressure monitor and conventional 24-hour ABPM demonstrated high agreement, fully meeting ESH error margin criteria." This confirms CART as a reliable tool for personalised HF treatment, Sky Labs said.
The CART blood pressure monitor enables continuous BP tracking even in AF and HF patients who previously faced measurement limitations with conventional cuffs due to irregular pulses or high variability.
Rznomics reports advances in high-efficiency circRNA production in Nucleic Acids Research
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA
Thryv Therapeutics licenses new class of SGK1 inhibitors, expanding into neurodegenerative disease
Sensorion secures French approval for Phase I/II SENS-601 hearing-loss trial
Foventa makes key CMO and CFO appointments
Akeso's ivonescimab meets overall survival endpoint in interim analysis of Phase III HARMONi-2 study
Teva reports positive Phase 2a data for TEV '408 in celiac disease
Ono Pharma partners with Aitia on neurological disease drug discovery
BioViva receives US patent for Klotho gene therapy targeting age-related cognitive decline
AstraZeneca completes global licence agreement for Zegfrovy
NeuroSense reveals strategy to advance PrimeC toward potential ALS approval
UCB agrees with US government to lower medicine costs and strengthen US manufacturing